2. Academic Validation
  3. Discovery of Anticancer Agents of Diverse Natural Origin

Discovery of Anticancer Agents of Diverse Natural Origin

  • J Nat Prod. 2022 Mar 25;85(3):702-719. doi: 10.1021/acs.jnatprod.2c00036.
Leslie N Aldrich 1,  Joanna E Burdette 2,  Esperanza Carcache de Blanco 3,  Christopher C Coss 3,  Alessandra S Eustaquio 2,  James R Fuchs 3,  A Douglas Kinghorn 3,  Amanda MacFarlane 4,  Brittney K Mize 3,  Nicholas H Oberlies 5,  Jimmy Orjala 2,  Cedric J Pearce 6,  Mitch A Phelps 3,  Liva Harinantenaina Rakotondraibe 3,  Yulin Ren 3,  Djaja Doel Soejarto 2 7,  Brent R Stockwell,  Jack C Yalowich 3,  Xiaoli Zhang 8
Affiliations

Affiliations

  • 1 Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607, United States.
  • 2 College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States.
  • 3 College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
  • 4 Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
  • 5 Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 24702, United States.
  • 6 Mycosynthetix, Inc., Hillsborough, North Carolina 27278, United States.
  • 7 Field Museum of Natural History, Chicago, Illinois 60605, United States.
  • 8 College of Medicine, The Ohio State University, Columbus, Ohio 43210, United States.
PMID: 35213158 DOI: 10.1021/acs.jnatprod.2c00036
Abstract

Research progress from mainly over the last five years is described for a multidisciplinary collaborative program project directed toward the discovery of potential Anticancer agents from a broad range of taxonomically defined organisms. Selected lead compounds with potential as new antitumor agents that are representative of considerable structural diversity have continued to be obtained from each of tropical Plants, terrestrial and aquatic cyanobacteria, and filamentous fungi. Recently, a new focus has been on the investigation of the constituents of U.S. lichens and their Fungal mycobionts. A medicinal chemistry and pharmacokinetics component of the project has optimized structurally selected lead Natural Products, leading to enhanced cytotoxic potencies against selected Cancer cell lines. Biological testing has shown several compounds to have in vivo activity, and relevant preliminary structure-activity relationship and mechanism of action studies have been performed. Several promising lead compounds worthy of further investigation have been identified from the most recent collaborative work performed.

Figures